Related Experiment Videos
Postmarketing safety information: how useful are spontaneous reports?
K Hartmann1, A K Doser, M Kuhn
1Swiss Drug Monitoring Center SANZ, Chur, Switzrland.
Pharmacoepidemiology and Drug Safety
|April 10, 2004
Summary
Physicians reported 250 adverse drug reactions (ADRs) for new chemical entities (NCEs) in Switzerland. Many ADRs were unlabelled and serious, highlighting the value of spontaneous reporting systems for drug safety.
Area of Science:
- Pharmacovigilance
- Drug Safety Monitoring
Background:
- 123 new chemical entities (NCEs) were launched in Switzerland between 1995 and June 1998.
- A voluntary spontaneous reporting scheme (SRS) collected adverse reaction reports.
Purpose of the Study:
- To analyze adverse drug reactions (ADRs) reported for new chemical entities (NCEs) in Switzerland.
- To assess the characteristics and implications of these ADRs.
Main Methods:
- Analysis of 250 spontaneous adverse reaction reports submitted to the Swiss Drug Monitoring Center SANZ.
- Focus on reports involving 56 different NCEs, excluding observational or clinical postmarketing studies.
Main Results:
- 88% of ADR reports were suspected to be drug-related, with 20% being serious.
- 64% of ADRs were unlabelled, with central nervous system and cardiovascular disorders prominent in serious, unlabelled cases.
- Skin reactions were the most frequent ADRs overall (18%).
Conclusions:
- Spontaneous reporting systems are crucial for enhancing postmarketing drug safety information.
- Early ADR reports can reveal safety profiles different from premarketing data.
- Effective signal detection systems are vital for identifying unlabelled and serious ADRs promptly.